Antiallergic Effects of Anti-Interleukin-33 are Associated with Suppression of Immunoglobulin Light Chain and Inducible Nitric Oxide Synthase

Abstract

Objective

We aimed to find novel genes that are significantly induced in allergic mice and that are significantly downregulated with anti-interleukin (IL) 33 treatment.

Methods

Thirty-six mice were allocated into each of group A (intraperitoneal [i.p.]) sensitized and intranasally challenged to saline solution), group B (sensitized and challenged to ovalbumin), group C (sensitized and challenged with ovalbumin, and null treatment with i.p. saline solution), and group D (sensitized and challenged with ovalbumin, and treatment with anti-IL-33 i.p. injection). We counted the number of nose-scratching in 10 minutes, serum ovalbumin-specific immunoglobulin E (IgE), and titers of cytokines (IL-1, IL-4, IL-5, IL-10, IL-13) in bronchoalveolar lavage fluid. By using one whole lung from each mouse, we performed microarray analysis and real-time polymerase chain reaction.

Results

Group D showed a significantly reduced nose-scratching events and lower serum ovalbumin-specific IgE compared with groups B and C. All the cytokines in the bronchoalveolar lavage fluid were significantly decreased after anti-IL-33 treatment. Microarray analysis revealed that group B (immunoglobulin free light chain [IgFLC], 89.1 times; nitric oxide synthase [NOS] 2,11.5 times) and group C (IgFLC, 141.6 times; NOS2,11.7 times) had significantly increased expression of IgFLC and NOS2 genes compared with group A. After anti-IL-33 treatment, group D showed significantly decreased expression of both IgFLC (49.3 times) and NOS2 (6.5 times). In real-time polymerase chain reaction, groups B and C had significantly increased expression of these genes (IgFLC, 10.4 times and 29 times, respectively; NOS2, 3.8 times and 4.5 times, respectively). After treatment, group D showed significantly decreased expression of IgFLC (5.0 times) and NOS2 (2.5 times).

Conclusion

The antiallergic effect of anti-IL-33 can be explained by suppression of IgFLC and NOS2 in a murine model of allergic rhinitis.

Get full access to this article

View all access options for this article.

References

Tago

Noda

Hayakawa

Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V.

Biochem Biophys Res Commun 285: 1377–1383, 2001

Moussion

Ortega

and Girard

J.P.

The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel ‘alarmin’?

PLoS One 3: e3331, 2008

Luthi

A.U.

Cullen

S.P.

McNeela

E.A.

Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.

Immunity 31: 84–98, 2009

Talabot-Ayer

Lamacchia

Gabay

and Palmer

Interleukin-33 is biologically active independently of caspase-1 cleavage.

J Biol Chem 284: 19420–19426, 2009

Kurowska-Stolarska

Hueber

Stolarski

and McInnes

I.B.

In-terleukin-33: A novel mediator with a role in distinct disease pathologies.

J Intern Med 269: 29–35, 2011

Iijima

Kobayashi

Hara

IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure.

J Immunol 193: 1549–1559, 2014

Canbaz

Utsch

Logiantara

IL-33 promotes the induction of immunoglobulin production after inhalation of house dust mite extract in mice.

Allergy 70: 522–532, 2015

Vocca

Di Sano

Uasuf

C.G.

IL-33/ST2 axis controls Th2/ IL-31 and Th17 immune response in allergic airway diseases.

Immunobiology 220: 954–963, 2015

Kaur

Gomez

Doe

IL-33 drives airway hyper-responsiveness through IL-13 mediated mast cell: Airway smooth muscle crosstalk.

Allergy 70: 556–567, 2015

10.

Kim

Y.H.

Yang

T.Y.

Park

C.S.

Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis.

Allergy 67: 183–190, 2012

11.

Hopper

J.E.

and Papagiannes

Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain.

Cell Immunol 101: 122–131, 1986

12.

Skvortsov

V.T.

and Gurvich

A.E.

Relative rates of synthesis of immu-noglobulins and light chains in rabbit spleen cells during secondary response.

Nature 218: 377–378, 1968

13.

Hannam-Harris

A.C.

and Smith

J.L.

Free immunoglobulin light chain synthesis by human foetal liver and cord blood lymphocytes.

Immunology 43: 417–423, 1981

14.

van der Heijden

Kraneveld

and Redegeld

Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases.

Eur J Pharmacol 533: 319–326, 2006

15.

Kawamoto

Takumida

Takeno

Localization of nitric oxide synthase in human nasal mucosa with nasal allergy.

Acta Otolaryngol Suppl 539: 65–70, 1998

16.

Kang

B.H.

Chen

S.S.

Jou

L.S.

Immunolocalization of inducible nitric oxide synthase and 3-nitrotyrosine in the nasal mucosa of patients with rhinitis.

Eur Arch Otorhinolaryngol 257: 242–246, 2000

17.

Kim

Y.H.

Park

C.S.

Lim

D.H.

Beneficial effect of anti-interleukin-33 on the murine model of allergic inflammation of the lower airway.

J Asthma 49: 738–743, 2012

18.

Lee

H.Y.

Rhee

C.K.

Kang

J.Y.

Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma.

Exp Lung Res 40: 66–76, 2014

19.

Bouffi

Rochman

Zust

C.B.

IL-33 markedly activates murine eosinophils by an NF-kappaB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop.

J Immunol 191: 4317–4325, 2013

20.

Schmitz

Owyang

Oldham

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.

Immunity 23: 479–490, 2005

21.

Grimbaldeston

M.A.

Nakae

Kalesnikoff

Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B.

Nat Immunol 8: 1095–1104, 2007

22.

Meng

Sha

The expression and significance of immunoglobulin free light chain in the patients with allergic rhinitis and nonallergic rhinitis.

Am J Rhinol Allergy 28: 302–307, 2014

23.

Kaplan

Aizenbud

B.M.

Golderman

Free light chain monomers in the diagnosis of multiple sclerosis.

J Neuroimmunol 229: 263–271, 2010

24.

Tekstra

van Roon

Groot Kormelink

and Redegeld

Immunoglobulin free light chain levels and rituximab response in rheumatoid arthritis: Comment on the article by Sellam, et al.

Arthritis Rheum 63: 4034–4035; author reply 4035, 2011

25.

Kaplan

Livneh

and Sela

B.A.

Immunoglobulin free light chain dimers in human diseases.

ScientificWorldJournal 11: 726–735, 2011

26.

Bradwell

A.R.

Carr-Smith

H.D.

Mead

G.P.

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Clin Chem 47: 673–680, 2001

27.

Kraneveld

A.D.

Kool

van Houwelingen

A.H.

Elicitation of allergic asthma by immunoglobulin free light chains.

Proc Natl Acad Sci U S A 102: 1578–1583, 2005

28.

Powe

D.G.

Groot Kormelink

Sisson

Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis.

J Allergy Clin Immunol 125: 139–145, 2010

29.

Jiang

Airway hyperresponsiveness induced by repetitive intraperitoneal injection of lipopolysaccharide and the involvement of inflammation and nitric oxide in guinea pigs.

Inflamm Res 55: 286–292, 2006

30.

Ten Broeke

De Crom

Van Haperen

Overexpression of endothelial nitric oxide synthase suppresses features of allergic asthma in mice.

Respir Res 7: 58, 2006

31.

Redington

A.E.

Meng

Q.H.

Springall

D.R.

Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment.

Thorax 56: 351–357, 2001

32.

King

N.E.

Rothenberg

M.E.

and Zimmermann

Arginine in asthma and lung inflammation.

J Nutr 134(suppl.): 2830S–2836S; discussion 2853S 2004

33.

Yuksel

Kirmaz

Yilmaz

Nasal mucosal expression of nitric oxide synthases in patients with allergic rhinitis and its relation to asthma.

Ann Allergy Asthma Immunol 100: 12–16, 2008

34.

Chiba

Matsuo

Sakai

Increased expression of inducible nitric oxide synthase in nasal mucosae of guinea pigs with induced allergic rhinitis.

Am J Rhinol 20: 336–341, 2006

35.

Struben

V.M.

Wieringa

M.H.

Feenstra

and de Jongste

J.C.

Nasal nitric oxide and nasal allergy.

Allergy 61: 665–670, 2006

36.

Xiong

Karupiah

Hogan

S.P.

Inhibition of allergic airway inflammation in mice lacking nitric oxide synthase 2.

J Immunol 162: 445–452, 1999

37.

Jiang

Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin.

PLoS Pathog 2014; 10: e1003918

38.

Rank

M.A.

Hagan

J.B.

Samant

S.A.

Kita

A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations: Data from a pilot study.

Am J Rhinol Allergy 27: 98–101, 2013

39.

Yoshimura

Moon

T.C.

St Laurent

C.D.

Expression of nitric oxide synthases in leukocytes in nasal polyps.

Ann Allergy Asthma Immunol 108: 172–177, 2012

40.

Baumann

Rabaszowski

Stenin

Nasal levels of soluble IL-33R ST2 and IL-16 in allergic rhinitis: Inverse correlation trends with disease severity.

Clin Exp Allergy 43: 1134–1143, 2013

41.

Seo

M.W.

Lee

G.Y.

Airway epithelial cells initiate the allergen response through transglutaminase 2 by inducing IL-33 expression and a subsequent Th2 response.

Respir Res 14: 35, 2013.